cGKI α Antibodies

Santa Cruz Biotechnology provides a broad selection of cGKI α monoclonal antibodies for research focused on understanding cyclic guanosine monophosphate-dependent protein kinase I alpha. The monoclonal antibodies are suitable for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). cGKI α plays a crucial role in mediating the effects of nitric oxide and cGMP signaling pathways, which are vital for cardiovascular function and smooth muscle relaxation. The signaling mechanisms regulated by cGKI α have significant implications for understanding both normal physiology and disease states. Researchers investigating cardiovascular disorders can utilize cGKI α monoclonal antibodies to examine protein expression and localization in various experimental models. Validated data and application protocols enable reliable detection of cGKI α in diverse experimental settings. Advanced research techniques supported by cGKI α monoclonal antibodies help reveal new insights about cellular signaling networks. Santa Cruz Biotechnology monoclonal antibodies for cGKI α contribute to advancing scientific knowledge in cardiovascular research and therapeutic development.